Good

Stories that celebrate innovation, and the good side of humanity, to give you hope.

Clinical trial gives hope for soothing agitation

Clinical trial gives hope for soothing agitation

by ALZHEIMER SOCIETY OF CANADA

One in five people with Alzheimer’s disease experience severe agitation.

While extreme restlessness is hard for anyone to bear, in those with dementia it may also speed the progression of the disease. Doctors don’t understand why, but they know that controlling agitation is important.

“It’s a quality of life issue,” says Dr. Krista Lanctôt, a senior researcher at Toronto’s Sunnybrook Research Institute and an expert in neuropsychiatric problems. “When people are agitated and have an inner turmoil, their obvious discomfort is hard to watch.”

Because the number of those with Alzheimer’s disease and other dementias is increasing exponentially, researchers are looking for ways to make the disease easier to live with.

When people are agitated and have an inner turmoil, their obvious discomfort is hard to watch.

That includes controlling agitation. But antipsychotic drugs currently used to treat it work only with some people. These drugs can contribute to cognitive decline in their own right, while also increasing risk of stroke.

That’s why Dr. Lanctôt, with the help of Sunnybrook’s Dr. Nathan Herrmann, is poised to launch a small clinical trial of a drug called nabilone that shows promise for treating agitation, without the side effects of antipsychotic drugs. It could also control pain and the weight loss common in those with Alzheimer’s disease.

Nabilone is a synthetic version of the active ingredient in marijuana plants. Cancer patients use it to treat chemotherapy-induced nausea, and those with anorexia use it to help stimulate appetite and regain weight. But it has never been properly tested in people with Alzheimer’s.

Launching this fall, Dr. Lanctôt’s study is co-funded by the Alzheimer Society Research Program and the Discovery Foundation of Canada.

It involves 40 participants with Alzheimer’s disease. Half will be randomly assigned to take nabilone for six weeks and then a placebo for six weeks, with a week in between when they take neither. The other half will begin with six weeks of placebo, followed by a week off, and then six weeks of nabilone.

Dr. Lanctôt will measure changes in agitation, reported pain and weight gain. If all goes well, she hopes to progress to a larger clinical trial.

No one with dementia should have to suffer severe agitation.

Help the Alzheimer Society of Canada continue to fund this kind of research by giving to the Alzheimer Society Research Program. More information is available at www.alzheimer.ca.



You might also enjoy:

Good News on the Alzheimer's Prevention Front

If you're like most of the people surveyed in a poll conducted by AARP, you're concerned about getting…

GPS TRACKING: DETECT DEMENTIA EARLIER?

Waterloo, Ont., researchers created an app that uses a cell phone GPS to prove the link between the…

Bride weds at Alzheimer's center

This story making the rounds online has touched our hearts – all thanks to a bride’s about-face.…

Dancing for Dementia

Like any recital, the Celtic Academy’s year-end Irish dance showcase in Walkerton, Ont., will attract…

comments powered by Disqus